Adjuvant nivolumab as SOC for high-risk muscle-invasive urothelial carcinoma after radical resection

(2:13)

CheckMate 274: adjuvant nivolumab versus placebo for urothelial carcinoma

(1:35)

Adjuvant nivolumab in patents with high-risk resected melanoma

(2:22)

Matthew Galsky on Adjuvant Nivolumab Trials

(2:18)

CheckMate 274: biomarkers linked to disease-free survival with adjuvant nivolumab

(2:19)

Checkmate 577 - Is Nivolumab adjuvant the standard of care in esophagus and GEJ?

(13:47)

Radiation and adjuvant nivolumab in HPV+ oropharynx cancer

(1:13)

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

(1:49)

Checkmate 274 Adjuvant Nivolumab in Urothelial Cancer | An Oncologist's Take

(12:12)

FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma

(5:)

Dr. Weber on Nivolumab in the Adjuvant Setting for Melanoma

(1:15)

Adjuvant nivolumab in resected oesophageal or GOJ cancer following chemo

(9:10)

4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma

(5:44)

7-year results from CheckMate 238: adjuvant nivolumab in melanoma

(2:3)

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with res...

(4:59)

Checkmate577: nivolumab in EC/GEJC

(5:18)

HCRN MEL17-309: Phase II study of adjuvant nivolumab with ipilimumab in high-risk uveal melanoma

(2:14)

Adjuvant and Neoadjuvant Dilemmas

(27:18)

Nivolumab for oesophageal cancer following chemoradiation therapy

(8:16)

IMMUNED: adjuvant nivolumab and ipilimumab increases OS in stage IV melanoma

(2:14)